Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562273 · ClinicalTrials.gov registry record
GammaPod Registry and Quality of Life Nomogram
A clinical trial of Breast Cancer Female, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- 160
- Enrollment target
- 4
- Study locations
NCT03562273: Recruiting study of Breast Cancer Female, sponsored by University of Maryland, Baltimore.
NCT03562273 is a study of Breast Cancer Female that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 160 participants, below the 689-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03562273, a study of Breast Cancer Female, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
Primary Outcome
Evaluate the quality of life impact shortening treatment by 3-4 fractions may have on a patient via questionnaire(s).
Conditions Studied
Interventions
- RADIATION Quality Of Life Sizing Nomogram
Study Locations (4)
Maryland
- Upper Chesapeake Health - Bel Air
- Central Maryland Oncology Center - Columbia
- Baltimore Washington Medical Center - Glen Burnie
Texas
- UTSouthwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2030-12 |
What NCT03562273 shows while recruiting
NCT03562273 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 689-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Quality Of Life Sizing Nomogram is the first listed.
NCT03562273 reports a single indexed study location in Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT03562273 about?
NCT03562273 is a clinical study titled "GammaPod Registry and Quality of Life Nomogram". This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
What is the current status of trial NCT03562273?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2019-01-03. Estimated completion is 2030-12.
What conditions does trial NCT03562273 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT03562273?
The interventions under investigation include: Quality Of Life Sizing Nomogram (RADIATION).
Who is sponsoring clinical trial NCT03562273?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03562273 being conducted?
This trial has 4 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03562273's enrollment target sits among peer trials
160 18th of 46 higher than 29 of 46 other Breast Cancer Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Resiliency Through Exercise Program (B-REP)
RECRUITING · NA
-
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI